FDA reportedly eyeing staff bonuses to accelerate drug reviews
Source: SeekingAlpha
2026-02-26 13:35:52 ET
More on leading drugmakers
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Kenvue effort to dismiss Tylenol case rejected by Texas judge
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
FDA reportedly eyeing staff bonuses to accelerate drug reviews
Johnson & Johnson
NASDAQ: JNJ
JNJ Trading
0.72% G/L:
$238.335 Last:
3,094,172 Volume:
$238.115 Open:
JNJ Latest News
March 08, 2026 12:26:00 pm
These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders
JNJ Stock Data
$577,845,337,264
2,385,202,151
0.01%
2802
N/A
Pharmaceuticals
Healthcare
US
New Brunswick
